Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience
- Authors
- Yoo, Shin Hye; Koh, Youngil; Kim, Dae-Young; Lee, Jung-Hee; Lee, Je-Hwan; Lee, Kyoo-Hyung; Yoon, Sung-Soo; Park, Seonyang; Park, Sung-Kyu; Hong, Dae-Sik; Yi, Hyeon Gyu; Kim, Chul-Soo; Jang, Ji Eun; Cheong, June-Won; Moon, Joonho; Min, Yoo Hong; Sohn, Sang Kyun; Kim, Inho
- Issue Date
- Apr-2017
- Publisher
- Springer Verlag
- Keywords
- Allogeneic hematopoietic stem cell transplantation; Acute leukemia; Chemorefractoriness; Graft-versus-host disease
- Citation
- Annals of Hematology, v.96, no.4, pp 605 - 615
- Pages
- 11
- Journal Title
- Annals of Hematology
- Volume
- 96
- Number
- 4
- Start Page
- 605
- End Page
- 615
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7687
- DOI
- 10.1007/s00277-017-2919-8
- ISSN
- 0939-5555
1432-0584
- Abstract
- Little is known about the characteristics that make patients with acute leukemia suitable for undergoing salvage therapy by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we analyzed the clinical outcomes of 223 patients with acute leukemia who underwent allo-HSCT while not in complete remission (CR). The primary end points were overall survival (OS) and CR rate. CR was achieved in 79.8% of patients after allo-HSCT. Acute graft-versus-host disease (GVHD) was significantly associated with CR (P = 0.045). During a median follow-up of 30.1 months, the median OS was 6.1 months. OS was significantly longer in patients with good or standard risk cytogenetic characteristics than in those with poor risk cytogenetic characteristics (P = 0.029, P = 0.030, respectively). Patients who received allo-HSCT from a matched sibling donor had better survival than those with unrelated donors (P = 0.015). Primary chemorefractoriness was not associated with poor survival (P = 0.071). The number of chemotherapies before allo-HSCT was significantly correlated with outcome (P = 0.006). Chronic GVHD was a strong predictor of a longer OS (P = 0.025). In conclusion, survival of patients with primary chemorefractory acute leukemia is not lower when treated upfront with allo-HSCT. Hence, allo-HSCT should be actively considered in such patients. Acute and chronic GVHD is associated with better outcomes patients with acute leukemia who have undergone allo-HSCT and not achieved CR.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7687)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.